Last reviewed · How we verify
Bazedoxifene/Conjugated Estrogen
Bazedoxifene acts as a selective estrogen receptor modulator (SERM) that provides estrogen-like benefits while blocking estrogen effects in breast tissue, combined with conjugated estrogens for menopausal symptom relief.
Bazedoxifene acts as a selective estrogen receptor modulator (SERM) that provides estrogen-like benefits while blocking estrogen effects in breast tissue, combined with conjugated estrogens for menopausal symptom relief. Used for Moderate to severe vasomotor symptoms associated with menopause, Prevention of postmenopausal osteoporosis.
At a glance
| Generic name | Bazedoxifene/Conjugated Estrogen |
|---|---|
| Also known as | Duavee |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Selective Estrogen Receptor Modulator (SERM) combined with Conjugated Estrogens |
| Target | Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Women's Health / Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Bazedoxifene is a SERM that selectively activates estrogen receptors in bone and the cardiovascular system while antagonizing them in breast tissue, reducing breast cancer risk. When combined with conjugated estrogens, it provides systemic estrogen replacement therapy for menopausal symptoms while the bazedoxifene component offers tissue-selective protection against estrogen-related adverse effects in the breast.
Approved indications
- Moderate to severe vasomotor symptoms associated with menopause
- Prevention of postmenopausal osteoporosis
Common side effects
- Hot flashes
- Vaginal bleeding/spotting
- Breast tenderness
- Headache
- Muscle pain
Key clinical trials
- Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers (EARLY_PHASE1)
- Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens (PHASE2)
- Raising Insulin Sensitivity in Post Menopause (EARLY_PHASE1)
- The PROMISE Study: Duavee in Women With DCIS (PHASE2)
- Advancing Postmenopausal Preventive Therapy (PHASE2)
- Affect of Duavive on Mood & Anxiety Symptoms (PHASE1)
- Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee (PHASE4)
- Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: